Alumis released new Phase 3 data for envudeucitinib, its investigational next-generation TYK2 inhibitor for plaque psoriasis. The update was presented at Fall Clinical 2026 in Las Vegas, underscoring the company’s push in psoriasis drug development.
published
Alumis released new Phase 3 data for envudeucitinib, its investigational next-generation TYK2 inhibitor for plaque psoriasis. The update was presented at Fall Clinical 2026 in Las Vegas, underscoring the company’s push in psoriasis drug development.
Latest documented BWB result
$SECZ market result
Exit $SECZ with .95 profit per share - thanks to a nice after hours pop. Will re-enter tomorrow most likely
Historical results are not a promise of future performance. Trading involves substantial risk.This public post is a timestamped information archive, not personalized financial advice. Alerts can change as markets move. Join Billy's private group for the complete daily stream and follow-through.